Full Year Results 

Synairgen trials treatment for Covid-19

Synairgen trials treatment for Covid-19

Think tank the Milken Institute is currently tracking over 200 potential Covid-19 treatments. One such candidate is SNG001, an inhalable drug produced by Aim-listed biotech minnow Synairgen (SNG). Following news in mid-March that SNG001 had been approved for testing in hospital patients, the shares have been on a tear, more than doubling in value to 50p.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now